

**MANGALAM DRUGS & ORGANICS LTD.**Regd. Off.: Rupam Building, 3<sup>rd</sup> Floor, P. D' Mello Road, Near G.P.O., Mumbai - 400 001.

CIN: L24230MH1972PLC116413

**Y-O-Y TOTAL INCOME****BY 80%****Y-O-Y EBIDTA****BY 109%****Y-O-Y PAT****TURNAROUND FROM  
LOSS TO PROFIT****A. AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31<sup>ST</sup> MARCH, 2015**

(₹ in Lacs)

Sr. No.	Particulars	Audited (Refer Note-2)	Unaudited			Audited	Audited
		3 months ended	Quarter Ended		Year Ended	Year Ended	
			Previous 3 months ended in the current year	Corresponding 3 months ended in the previous year	Current accounting year ended	Previous accounting year ended	
		31.03.15	31.12.14	31.03.14	31.03.15	31.03.14	
1	Sales / Income from operation (Net of Excise duty)	8039.31	6078.34	3777.48	22058.39	12251.61	
2	Other Operating Income	(481.50)	216.26	14.93	7.47	16.15	
3	Total Net Income from Operation	7557.81	6294.60	3792.41	22065.86	12267.76	
4	Expenditure						
a)	Increase / decrease in stock in trade & work in progress	(1297.80)	(346.45)	(434.77)	(745.54)	(544.63)	
b)	Consumption of raw materials	6917.90	4941.79	2772.57	16324.04	8374.88	
c)	Employees Cost	274.62	292.31	224.30	1095.20	1024.55	
d)	Depreciation	114.60	100.27	101.43	415.40	401.05	
e)	Other expenditure	1060.01	906.45	621.54	3352.68	2436.55	
f)	Total	7069.33	5894.37	3285.07	20441.78	11692.40	
5	Profit (+) / Loss (-) from operations before Other income, Finance cost and Exceptional Items (3-4)	488.48	400.23	507.34	1624.08	575.36	
6	Other income	0.29	0.00	2.46	5.17	8.23	
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items (5+6)	488.77	400.23	509.80	1629.25	583.59	
8	Finance Cost	212.63	270.75	206.94	1028.37	974.21	
9	Profit (+) / Loss (-) from ordinary activities after Finance cost & Exceptional Items (7-8)	276.14	129.48	302.86	600.88	(390.62)	
10	Exceptional Items	0.00	0.00	0.00	0.00	0.00	
11	Profit (+) / Loss (-) before Tax (9-10)	276.14	129.48	302.86	600.88	(390.62)	
12	Tax Expenses (incl Deferred Tax less Mat Credit entitlement)	(73.24)	45.00	(86.71)	(13.24)	(86.71)	
13	Net Profit (+) / Loss (-) after Tax (11-12)	349.38	84.48	389.57	614.12	(303.91)	
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	
15	Net Profit (+) / Loss (-) for the period (13-14)	349.38	84.48	389.57	614.12	(303.91)	
16	Paid up Equity Share Capital (face value ₹ 10/-each)	1317.82	1317.82	1317.82	1317.82	1317.82	
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	1618.59	0.00	1004.47	1618.59	1004.47	
18	Earning per share (EPS)						
a)	Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	2.65	0.64	2.96	4.66	(2.31)	
b)	Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	2.65	0.64	2.96	4.66	(2.31)	
19	Non Promoters Shareholding						
-	Number of shares	7628115	7628115	7628115	7628115	7628115	
-	Percentage of shareholding	57.88	57.88	57.88	57.88	57.88	
20	Promoters and Promoter group Shareholding						
a)	Pledged / Encumbered						
-	Number of Shares	4050133	5491228	5491228	4050133	5491228	
-	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	72.97	98.94	98.94	72.97	98.94	
-	Percentage of Shares (as a % of the total share capital of the company)	30.73	41.67	41.67	30.73	41.67	
b)	Non-encumbered						
-	Number of Shares	1500000	58905	58905	1500000	58905	
-	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	27.03	1.06	1.06	27.03	1.06	
-	Percentage of Shares (as a % of the total share capital of the company)	11.39	0.45	0.45	11.39	0.45	

**Notes:**

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 15<sup>th</sup> May 2015.
- The results for the quarter ended March 31, 2015 are derived figures arrived at by subtracting the results for the nine months ended on December 31, 2014 from the audited results for the year ended March 31, 2015. For the quarter ended March 31, 2015 and year ended March 31, 2015 amount of excise duty refund shown in other income is considered as Sales / Income from operations.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk drugs" the disclosure requirement of Accounting Standard (AS-17) "Segment Reporting" is not applicable.
- During the Quarter & Year ended 31<sup>st</sup> March 2015, 0 Investor complaint were received, all of which have been attended by the company. No complaints were pending at the beginning or at the end of the quarter.
- Previous year figure are regrouped wherever necessary.

**STATEMENT OF ASSETS & LIABILITIES AS REQUIRED UNDER CLAUSE 41 OF LISTING AGREEMENT**

(₹ In Lacs)

Sr. No.	Particulars	As at 31 March, 2015	As at 31 March, 2014
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>Shareholders' funds</b>		
a)	Share capital	1,317.82	1,317.82
b)	Reserves and surplus	1,618.59	1,004.47
	<b>Sub Total -Shareholders Funds</b>	<b>2,936.41</b>	<b>2,322.29</b>
2	<b>Non-current liabilities</b>		
a)	Long-term borrowings	3,937.04	4,020.21
b)	Deferred Tax Liabilities (Net)	169.80	58.56
	<b>Sub Total -Non-Current Liabilities</b>	<b>4,106.84</b>	<b>4,078.77</b>
3	<b>Current liabilities</b>		
a)	Short-term borrowings	3,182.43	3,136.67
b)	Trade payables	5,477.29	2,086.73
c)	Other current liabilities	1,286.53	919.97
	<b>Sub Total -Current Liabilities</b>	<b>9,946.25</b>	<b>6,143.37</b>
	<b>TOTAL</b>	<b>16,989.50</b>	<b>12,544.43</b>
<b>B</b>	<b>ASSETS</b>		
1	<b>Non-current assets</b>		
a)	Fixed Assets	5294.79	5338.43
b)	Long-term loans and advances	91.02	64.50
	<b>Sub Total -Non-Current Assets</b>	<b>5,385.81</b>	<b>5,402.93</b>
2	<b>Current assets</b>		
a)	Current Investments	24.02	17.92
b)	Inventories	5,734.04	3,647.76
c)	Trade receivables	4,424.69	2,968.73
d)	Cash and cash equivalents	67.94	10.23
e)	Short-term loans and advances	1,353.00	496.86
	<b>Sub Total -Current Assets</b>	<b>11,603.69</b>	<b>7,141.50</b>
	<b>TOTAL</b>	<b>16,989.50</b>	<b>12,544.43</b>

Notes: 1) Previous periods / years figures have been regrouped / rearranged wherever necessary.

On behalf of Board of Directors  
For Mangalam Drugs & Organics LtdPlace : Mumbai  
Date : 15.05.2015Director  
(Shri Govardhan M. Dhoot)